Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive…
Read the full articleYou might also wanna read
Elutia (ELUT) Finalizes Sale of SimpliDerm Business for Up to $11M
Related Stocks: ELUT
Novartis’ $1.5 Billion Myricx Deal Tests Oncology Pipeline
Novartis (NYSE:NVS) has made another clear move toward oncology depth, agreeing to acquire U.K.-based Myricx Bio for up to $1.5 billion. The
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipi
NextCure (NASDAQ: NXTC) plans reverse merger; Avere holders to own about 98%
NextCure will seek stockholder approval to issue merger and financing shares, effect a reverse stock split if needed, increase authorized co
Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis
Myricx Bio, a cancer therapy spinout based on research carried out at the Francis Crick Institute and Imperial College London, has reached a
crick.ac.uk·10d agoEvonik Aktie: 650 Millionen EBITDA im Q2 erwartet
Evonik schaltet in den Angriffsmodus. Der Spezialchemie-Konzern investiert massiv in den USA. Parallel dazu hebt die Führung ihre Gewinnziel
Comments
Sign in to join the conversation.
No comments yet. Be the first.